A life sciences company can look remarkably healthy from the outside while carrying a significant organizational risk inside: too much of what matters sits with one person.
It might be the founder who knows every detail of the science and every investor relationship. It might be the Chief Medical Officer who has been involved in every clinical decision since the program began. It could be the regulatory leader who understands the history behind every interaction with the FDA or EMA. Sometimes it is the commercial executive who knows every major customer, partner, and market assumption.
These individuals are invaluable. They are also potential points of organizational fragility.
The problem is not that a company depends on exceptional people. Every successful organization does. The problem begins when institutional knowledge, relationships, decision-making authority, and critical context become so concentrated that the organization struggles to function without one individual.
For growing biotech, pharma, and medtech companies, that distinction deserves far more attention.
When expertise becomes organizational dependency
Early-stage companies naturally concentrate knowledge. There are fewer employees, fewer layers of management, and limited resources. The founding team often carries an extraordinary amount of institutional memory simply because they were there when the critical decisions were made.
That is perfectly normal.
The risk appears when the company continues operating that way as complexity increases.
A clinical program progresses. The organization adds employees. Investors become more involved. New regulatory interactions occur. Partnerships are negotiated. Yet the same executive remains the person everyone turns to when something important happens.
Over time, the individual becomes the organization’s memory.
They know why a particular decision was made three years ago. They know which assumptions changed after a regulatory meeting. They remember the investor conversation that shaped a financing strategy. They understand which internal relationships are strong, and which require careful management.
That knowledge has enormous value. But if it exists primarily inside one person’s head, the organization has created a form of operational risk that may not appear on any conventional risk register.
The departure problem is only part of the issue
The obvious concern is what happens if a lynchpin executive leaves. But waiting for a resignation to expose the problem misses the larger issue.
Organizations can become dependent on a single leader even when that person has no intention of leaving. Decisions may bottleneck around them. Other executives may defer unnecessarily. Emerging leaders may have fewer opportunities to develop independent judgment. Teams can become accustomed to asking, “What does she think?” rather than asking, “What does the organization need?”
This can gradually weaken the leadership bench.
The executive at the center of the system may unintentionally become a constraint on organizational development precisely because they are so capable.
That is particularly dangerous during periods of growth. Organizations often discover that structures which worked effectively at an earlier stage become increasingly difficult to sustain as complexity increases. The challenge is not always individual performance. Sometimes the system has simply outgrown its original design.
Institutional knowledge needs somewhere to go
Strong organizations do not try to eliminate key people. They make their knowledge transferable. That requires more than documentation.
It means deliberately creating overlapping expertise, developing second-line leaders, involving multiple executives in important external relationships, and ensuring that critical decisions can be understood beyond the person who originally made them.
For example, a CMO preparing for a major regulatory milestone should not be the only executive who understands the history behind the program. A CEO should not be the sole holder of institutional relationships with investors. A founder should not be the only person capable of explaining the scientific rationale behind the company’s strategy.
This is not about making everyone interchangeable. It is about making the organization resilient.
The leadership bench becomes a strategic asset
Leadership depth is often discussed as a succession issue. It is more useful to think of it as an enterprise capability.
A company with several executives capable of taking on greater responsibility has options. It can respond to unexpected events more effectively. It can create internal mobility. It can expand into new markets without rebuilding its leadership structure from scratch.
It also becomes easier to make difficult decisions.
When too much authority sits with one executive, organizations can become psychologically reluctant to challenge that person. Even when the executive welcomes debate, others may hesitate because they assume the person with the deepest knowledge must also have the best answer.
But knowledge and judgment are not the same thing.
The strongest leadership teams create environments where expertise informs decisions without determining them automatically.
What boards should be asking
Boards can play an important role by asking questions that go beyond traditional succession planning.
- If this executive were unavailable for six months, what would become difficult?
- Who else understands this program?
- Which external relationships depend almost entirely on one person?
- Where does critical institutional knowledge reside?
- Which decisions are unnecessarily centralized?
And perhaps most importantly: who is becoming capable of doing more?
These questions reveal organizational resilience in a way that an org chart cannot.
They also help distinguish a genuinely strong leadership team from a collection of exceptionally talented individuals.
The goal is not to replace indispensable people
There is a temptation to interpret key-person risk as an argument for reducing dependence on high-performing executives. That would miss the point.
The best organizations will always have people who are unusually valuable. The objective is to make their contribution scalable.
An exceptional leader should leave the organization stronger because they were there and not more vulnerable because they were there.
That means building systems, relationships, and leadership capability around exceptional individuals while they are still in the organization, rather than scrambling to recreate their knowledge after they leave.
In a sector where a single clinical decision, regulatory interaction, financing event, or partnership can materially change enterprise value, organizational resilience is not an abstract leadership concept. It is part of strategic risk management.
The companies that build deep leadership benches are better prepared not only for unexpected departures, but for growth itself.
GeneCoda® works with life sciences boards and leadership teams to assess executive capability, succession risk, and the leadership depth required for the next stage of growth. If too much of your organization’s knowledge or decision-making sits with one person, contact us to discuss how to strengthen the leadership bench before it becomes a business risk.
